We are live on ! Find out more
ATRC icon

AtriCure

201 hedge funds and large institutions have $1.6B invested in AtriCure in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 78 increasing their positions, 72 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 72

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1% less capital invested

Capital invested by funds: $1.62B → $1.6B (-$21.9M)

4.19% less ownership

Funds ownership: 103%98.81% (-4.2%)

9% less funds holding

Funds holding: 221201 (-20)

51% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 35

Holders
201
Holders Change
-20
Holders Change %
-9.05%
% of All Funds
2.65%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
78
Reduced
72
Closed
35
Calls
$1.1M
Puts
Net Calls
+$1.1M
Net Calls Change
+$194K

ATRC Hedge Fund Activity: Q2 2025 in Review

201 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q2 2025, worth a combined $1.6B — down 1.3% from $1.62B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ATRC and 17 opened new positions — a net loss of 18 holders — while 72 trimmed existing stakes and 78 added.

The largest buyer was Wellington Management Group, adding an estimated $106M. The largest seller was UBS AM, cutting an estimated $32.3M.

  • 201 institutional investors held AtriCure (ATRC) as of Q2 2025, down from 221 in Q1 2025.
  • Funds reported $1.6B of AtriCure stock for Q2 2025, down 1.3% quarter-over-quarter.
  • 17 funds opened new AtriCure positions in Q2 2025 and 35 closed out, a net change of -18 holders.
  • The largest AtriCure buyer in Q2 2025 was Wellington Management Group, an estimated $106M added.
  • The largest AtriCure seller in Q2 2025 was UBS AM, an estimated $32.3M sold.

Based on aggregated 13F filings for Q2 2025.